Shenzhen New Industries Biomedical

Snibe announced on September 28 that it has received one Medical Device Registration Certificate issued by the National Medical Products Administration. In the first half of 2026, Snibe achieved revenue of 2.42 billion yuan and net profit attributable to the parent of 868 million yuan.

Shenzhen New Industries Biomedical Engineering Co., Ltd. announced on August 24, 2026, that its Angiotensin-Converting Enzyme Assay Kit (FAPGG Substrate Method) has obtained a Medical Device Registration Certificate issued by the Guangdong Medical Products Administration. The product is registered as Class II, with registration certificate number Yue Xie Zhu Zhun 20262400924, valid from August 19, 2026, to August 18, 2031. It is used for the in vitro quantitative determination of angiotensin-converting enzyme activity in human serum or plasma, and is clinically indicated for drug monitoring in hypertension and auxiliary diagnosis of sarcoidosis. The company stated that this product enriches the hypertension category within its biochemical testing portfolio and will not have a significant impact on recent production, operations, or financial performance.

Snibe released its 2026 interim report on August 14, 2026. Total operating revenue was 2.42 billion yuan, net profit attributable to the parent company was 868 million yuan, and net cash inflow from operating activities was 901 million yuan. The latest asset-liability ratio was 8.14 percent, up 1.00 percentage point from the previous quarter and up 0.65 percentage point from the same period last year. The latest gross margin was 70.88 percent, down 2.60 percentage points from the previous quarter. The latest return on equity was 9.67 percent, and diluted earnings per share was 1.11 yuan. The latest total asset turnover was 0.25 times, the latest inventory turnover was 0.67 times, the number of shareholders was 22,200, and the top ten shareholders held 514 million shares, accounting for 65.43 percent of total share capital.

New Industries released its 2026 interim report, with net profit attributable to the parent company of 868 million yuan, up 12.53% from the same period last year. Total operating revenue was 2.42 billion yuan, up 10.78% year on year. Net cash inflow from operating activities was 901 million yuan, up 95.29% year on year. The company's latest gross margin was 70.88%, an increase of 2.45 percentage points from the same period last year. Diluted earnings per share were 1.11 yuan, up 12.67% year on year.